Products and Methods for Treatment of Amyotrophic Lateral Sclerosis
AssigneesResearch Institute At Nationwide Children's Hospital, Ludwig Institute for Cancer Research
InventorsBrian K. Kaspar, Kevin Foust, Don W. Cleveland
Life of this patent
Estimating the term…
Abstract
The present invention relates to RNA-based methods for inhibiting the expression of the superoxide dismutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression of SOD-1. The methods have application in the treatment of amyotrophic lateral sclerosis.
Claims11
A recombinant adeno-associated virus comprising the superoxide dismutase 1 (SOD1) shRNA-encoding DNA:
- (SEQ ID NO:
- 1)
- GCATCATCAATTTCGAGCAGAAGGAA,
- (SEQ ID NO:
- 2)
- GAAGCATTAAAGGACTGACTGAA,
- (SEQ ID NO:
- 3)
- CTGACTGAAGGCCTGCATGGATT,
- (SEQ ID NO:
- 4)
- CATGGATTCCATGTTCATGA,
- (SEQ ID NO:
- 5)
- GCATGGATTCCATGTTCATGA,
- (SEQ ID NO:
- 6)
- GGTCTGGCCTATAAAGTAGTC,
- (SEQ ID NO:
- 7)
- GGGCATCATCAATTTCGAGCA,
- (SEQ ID NO:
- 8)
- GCATCATCAATTTCGAGCAGA,
- (SEQ ID NO:
- 9)
- GCCTGCATGGATTCCATGTTC,
- (SEQ ID NO:
- 10)
- GGAGGTCTGGCCTATAAAGTA,
- (SEQ ID NO:
- 11)
- GATTCCATGTTCATGAGTTTG,
- (SEQ ID NO:
- 12)
- GGAGATAATACAGCAGGCTGT,
- (SEQ ID NO:
- 13)
- GCTTTAAAGTACCTGTAGTGA,
- (SEQ ID NO:
- 14)
- GCATTAAAGGACTGACTGAAG,
- (SEQ ID NO:
- 1)
- GCATCATCAATTTCGAGCAGAAGGAA,
- (SEQ ID NO:
- 2)
- GAAGCATTAAAGGACTGACTGAA,
- (SEQ ID NO:
- 3)
- CTGACTGAAGGCCTGCATGGATT,
- (SEQ ID NO:
- 4)
- CATGGATTCCATGTTCATGA,
- (SEQ ID NO:
- 5)
- GCATGGATTCCATGTTCATGA,
- (SEQ ID NO:
- 6)
- GGTCTGGCCTATAAAGTAGTC,
- (SEQ ID NO:
- 7)
- GGGCATCATCAATTTCGAGCA,
- (SEQ ID NO:
- 8)
- GCATCATCAATTTCGAGCAGA,
- (SEQ ID NO:
- 9)
- GCCTGCATGGATTCCATGTTC,
- (SEQ ID NO:
- 10)
- GGAGGTCTGGCCTATAAAGTA,
- (SEQ ID NO:
- 11)
- GATTCCATGTTCATGAGTTTG,
- (SEQ ID NO:
- 12)
- GGAGATAATACAGCAGGCTGT,
- (SEQ ID NO:
- 13)
- GCTTTAAAGTACCTGTAGTGA,
- (SEQ ID NO:
- 14)
- GCATTAAAGGACTGACTGAAG,
- (SEQ ID NO:
- 15)
- TCATCAATTTCGAGCAGAA,
- (SEQ ID NO:
- 16)
- TCGAGCAGAAGGAAAGTAA,
- (SEQ ID NO:
- 17)
- GCCTGCATGGATTCCATGT,
- (SEQ ID NO:
- 18)
- TCACTCTCAGGAGACCATT,
- or
- (SEQ ID NO:
- 19)
- GCTTTAAAGTACCTGTAGT,
- wherein the recombinant adeno-associated virus genome lacks rep and cap genes.
A method of delivering the SOD1 shRNA-encoding DNA GCATCATCAATTTCGAGCAGAAGGAA (SEQ ID NO:1) to a subject in need thereof, comprising administering to the subject a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA GCATCATCAATTTCGAGCAGAAGGAA (SEQ ID NO:1), wherein the recombinant adeno-associated virus genomre lacks rep and cap genes.
A method of delivering the SOD1 shRNA-encoding DNA GAAGCATTAAAGGACTGACTGAA (SEQ ID NO:2) to a subject in need thereof, comprising administering to the subject a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA GAAGCATTAAAGGACTGACTGAA (SEQ ID NO:2), wherein the recombinant adeno-associated virus genome lacks rep and cap genes.
A method of delivering the SOD1 shRNA-encoding DNA CTGACTGAAGGCCTGCATGGATT (SEQ ID NO:3) to a subject in need thereof, comprising administering to the subject a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA CTGACTGAAGGCCTGCATGGATT (SEQ ID NO:3), wherein the recombinant adeno-associated virus genome lacks rep and cap genes.
A method of delivering the SOD1 shRNA-encoding DNA CATGGATTCCATGTTCATGA (SEQ ID NO:4) to a subject in need thereof, comprising administering to the subject a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA CATGGATTCCATGTTCATGA (SEQ ID NO:4), wherein the recombinant adeno-associated virus gemone lacks rep and cap genes.
A method of treating amyotrophic lateral sclerosis (ALS) comprising administering a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA GCATCATCAATTTCGAGCAGAAGGAA (SEQ ID NO:1), wherein the recombinant adeno-associated virus genome lacks rep and cap genes.
A method of treating ALS comprising administering a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA GAAGCATTAAAGGACTGACTGAA (SEQ ID NO:2), wherein the recombinant adeno-associated virus lacks rep and cap genes.
A method of treating ALS comprising administering a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA CTGACTGAAGGCCTGCATGGATT (SEQ ID NO:3), wherein the recombinant adeno-associated virus lacks rep and cap genes.
A method of treating ALS comprising administering a recombinant adeno-associated virus comprising the SOD1 shRNA-encoding DNA CATGGATTCCATGTTCATGA (SEQ ID NO:4), wherein the recombinant adeno-associated virus lacks rep and cap genes.
Dependencies are inferred from the claim text.